Improving Diagnosis and Care for Patients With Sarcoma: Do Real-World General Practitioners Data and Prospective Data Collections Have a Place Next to Clinical Trials? A thorough literature search was ...

Erratum: Clonal MET Amplification as a Determinant of Tyrosine Kinase Inhibitor Resistance in Epidermal Growth Factor Receptor–Mutant Non–Small-Cell Lung Cancer ...

Liquid biopsy techniques using cell-free DNA (cfDNA) play an increasingly important role in the characterization and surveillance of solid tumors. For blood cancers, molecular response assessment ...

There is an increasing interest in studying the potential of mobile health (mHealth) technologies, such as smartphone apps and wearables, as monitoring tools for patients with cancer during or after ...

Clinical Management of Ovarian Function Suppression in Premenopausal Women With Breast Cancer: A Survey of Members of ASCO In 2017, the National Cancer Institute (NCI) funded the Cancer Center ...

How to Keep Up With Molecular Testing and Targeted Therapies in Lung Cancer Over the next few years, the analysis of circulating tumor DNA (ctDNA) through liquid biopsy is expected to enter clinical ...

Interpretation of Reports and Translation to Community Oncologists: An Overview of Approaches Circulating tumor DNA (ctDNA) refers to DNA fragments released from cancer cells into the bloodstream.

Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.2 The following represents disclosure information provided by authors of this manuscript.

Not so long ago, clinical trials in oncology consisted of testing new chemotherapy drugs or pitting one chemotherapy drug against another in a conventional phase I-III sequence. How times have changed ...